SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+10.1%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$558M
AUM Growth
+$558M
(+14%)
Cap. Flow
+$28M
Cap. Flow
% of AUM
5.02%
Top 10 Holdings %
Top 10 Hldgs %
37.48%
Holding
150
New
25
Increased
36
Reduced
26
Closed
23
Top Buys
| 1 |
CEL
Cellcom Israel, Ltd.
CEL
|
$14.3M |
| 2 |
AGN
Allergan plc
AGN
|
$12.3M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$7.04M |
| 4 |
Merck
MRK
|
$6.72M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$6.38M |
Top Sells
| 1 |
Novartis
NVS
|
$16M |
| 2 |
Bristol-Myers Squibb
BMY
|
$13.8M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$12.2M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$3.99M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$3.63M |
Sector Composition
| 1 | Healthcare | 79.06% |
| 2 | Technology | 7.13% |
| 3 | Communication Services | 3.32% |
| 4 | Industrials | 1.33% |
| 5 | Financials | 1.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EIGR
26
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $5.72M | 0.82% | 520,269 +134,968 | +35% | +$1.48M |
|
|
RXDX
27
DELISTED
Ignyta, Inc.
RXDX
| $5.67M | 0.81% | 459,300 +59,300 | +15% | +$732K |
|
28
Alphabet (Google) Class A
GOOGL
$2.57T
| $5.62M | 0.8% | 5,767 +1,421 | +33% | +$1.38M |
|
29
Visa
V
$683B
| $5.57M | 0.8% | 52,951 | – | – |
|
30
Meta Platforms (Facebook)
META
$1.86T
| $5.5M | 0.78% | 32,167 | – | – |
|
31
Neurocrine Biosciences
NBIX
$13.8B
| $5.33M | 0.76% | 87,000 +25,000 | +40% | +$1.53M |
|
|
LJPC
32
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $5.22M | 0.74% | 150,000 +25,000 | +20% | +$870K |
|
|
AVEO
33
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $5.11M | 0.73% | 1,400,000 -800,000 | -36% | -$2.92M |
|
|
ZGNX
34
DELISTED
Zogenix, Inc.
ZGNX
| $5.08M | 0.73% | +145,000 | New | +$5.08M |
|
|
ARRY
35
DELISTED
Array Biopharma Inc
ARRY
| $4.98M | 0.71% | 405,000 -295,000 | -42% | -$3.63M |
|
36
Savara
SVRA
$567M
| $4.92M | 0.7% | 526,315 | – | – |
|
37
Charter Communications
CHTR
$36.3B
| $4.86M | 0.69% | 13,362 | – | – |
|
38
Minerva Neurosciences
NERV
$16.5M
| $4.75M | 0.68% | 625,000 +151,231 | +32% | +$1.15M |
|
39
Ascendis Pharma
ASND
$11.8B
| $4.69M | 0.67% | 129,474 -32,143 | -20% | -$1.17M |
|
40
Sapiens International
SPNS
$2.4B
| $4.65M | 0.66% | 354,866 +207,560 | +141% | +$2.72M |
|
41
Travere Therapeutics
TVTX
$1.56B
| $4.33M | 0.62% | 174,131 -35,000 | -17% | -$871K |
|
42
Insmed
INSM
$28.8B
| $4.21M | 0.6% | +135,000 | New | +$4.21M |
|
43
Cartesian Therapeutics
RNAC
$261M
| $4.17M | 0.6% | 228,534 | – | – |
|
44
SPDR Gold Trust
GLD
$107B
| $4.04M | 0.58% | +33,190 | New | +$4.04M |
|
|
GBT
45
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.94M | 0.56% | 127,000 -23,000 | -15% | -$714K |
|
46
Prothena Corp
PRTA
$441M
| $3.89M | 0.55% | 60,000 +20,000 | +50% | +$1.3M |
|
47
MacroGenics
MGNX
$112M
| $3.86M | 0.55% | 208,700 +127,500 | +157% | +$2.36M |
|
48
CytomX Therapeutics
CTMX
$336M
| $3.82M | 0.54% | 210,000 +10,000 | +5% | +$182K |
|
|
KDMN
49
DELISTED
Kadmon Holdings, Inc.
KDMN
| $3.69M | 0.53% | +1,100,000 | New | +$3.69M |
|
50
PDS Biotechnology
PDSB
$57.8M
| $3.58M | 0.51% | 333,737 +183,737 | +122% | +$1.97M |
|